Hopp til innhold
NHI.no
Annonse

Herpes genitalis: Smitte

Innhold i artikkelen

Medikamentell behandling erstatter ikke andre tiltak for å hindre spredningen av denne seksuelt overførte infeksjonen. Faren for å smitte partneren din er størst i forbindelse med et utbrudd. Du bør bruke kondom, og du bør informere partneren din om at du har en smittsom infeksjon. Gjennom medikamentell behandling og kondombruk elimineres ikke risikoen for å smitte andre, men sjansen for smitte blir mindre. Områder som kondomet ikke dekker, kan være smittet og kan da også overføre smitte.

Annonse

Selv når en person som vet at han/hun har herpes, ikke legger merke til noe sår, så kan smitte overføres i kortere perioder. Derfor anbefales det alltid å bruke kondom. Personer som er i faste parforhold, kan imidlertid velge å leve med en viss risiko for smitteoverføring dersom de ikke ønsker å bruke kondom hele tiden.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Herpes genitalis hos kvinner . Referanselisten for dette dokumentet vises nedenfor

  1. Groves MJ. Genital herpes: a review. Am Fam Physician. 2016 Jun 1;93(11):928-934.
  2. Blystad H. Herpes simplexvirus-infeksjoner - veileder for helsepersonell. Smittevernveilederen fra Folkehelseinstituttet. Sist endret juli 2014.
  3. Bernstein DI, Bellamy AR, Hook EW III, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013;56(3):344–351.
  4. Hartgill U, Peterson H, Rimstad L. Vulvovaginale infeksjoner. Veileder i generell gynekologi. Norsk gynekologisk forening, 2015. legeforeningen.no
  5. Kimberlin DW, Rouse DJ. Genital herpes. N Engl J Med 2004; 350: 1970-7. PubMed
  6. Tata S, Johnston C, Huang ML, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis. 2010;201(4):499–504.
  7. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342: 844-50. DOI: 10.1056/NEJM200003233421203 DOI
  8. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341: 1432 - 8. New England Journal of Medicine
  9. Tronstein E, Johnston C, Huang M-L, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011; 305: 1441-9. Journal of the American Medical Association
  10. Donovan B. Sexually transmissible infections other than HIV. Lancet 2004; 363: 545-56. PubMed
  11. Lautenschlager S, Eichmann A. The heterogeneous clinical spectrum of genital herpes. Dermatology 2001; 202: 211-9. PMID: 11385226 PubMed
  12. Wald A, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003;188(9):1345–1351.
  13. Nilsen A. Systemisk antiviral behandling ved herpes genitalis. Tidsskr Nor Lægeforen 2002; 122: 2805-6. PubMed
  14. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: genital HSV infections.. Accessed March 1, 2016. www.cdc.gov
  15. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transm Infect. 2002;78(3):160–165.
  16. Bradley H, et al. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J Infect Dis. 2014;209(3):325–333.
  17. Drake S, Taylor S, Brown D, Pillay D. Improving the care of patients with genital herpes. BMJ 2000; 321:619-23. British Medical Journal
  18. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al, for the valacyclovir HSV transmission study group. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350: 11-20. New England Journal of Medicine
  19. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012; doi:10.1016/S0140-6736(11)61750-9. DOI
  20. Skiveren J, Bermark S, et al.: Klinisk retningslinje for rensning af akutte og kroniske sår: Sæbe, skyllevæsker og skylletryk. Sist revidert 31.07.2017. Center for kliniske retningslinjer, Aalborg Universitet. www.cfkr.dk
  21. Le Cleach L, Trinquart L, Do G, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev. 2014 8:CD009036. doi: 10.1002/14651858.CD009036.pub2. DOI
  22. Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database of Systematic Reviews 2008; 1: CD004946. Cochrane (DOI)
  23. Pasternak B, Hviid A, . Use of acyclovir, valacyklivir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304: 859-66. Journal of the American Medical Association
  24. Stephenson-Famy A, Gardella C. Herpes simplex virus infection during pregnancy. Obstet Gynecol Clin North Am. 2014;41(4):601–614.
  25. Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84: 548-53. PubMed
  26. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366: 34-43. New England Journal of Medicine
  27. Dunphy K. Herpes genitalis and the philosopher's stance. J Med Ethics. 2014;40(12):793–797.
  28. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83. PubMed
  29. Corey L. Synergistic copathogens—HIV-1 and HSV-2. N Engl J Med. 2007;356(8):854–856.
Annonse
Annonse